Phillips, Samuel
Cassells, Kahli
Garland, Suzanne M.
Machalek, Dorothy A.
Roberts, Jennifer M.
Templeton, David J.
Jin, Fengyi
Poynten, I. Mary
Hillman, Richard J.
Grulich, Andrew E.
Murray, Gerald L.
Tabrizi, Sepehr N.
Molano, Monica
Cornall, Alyssa M.
,
Funding for this research was provided by:
Cancer Council Victoria
Cancer Council New South Wales
National Health and Medical Research Council
Article History
Received: 4 April 2021
Accepted: 8 February 2022
First Online: 3 March 2022
Competing interests
: J.M. Roberts reports other from Hologic Australia (Thin Prep consumables) during the conduct of the study and other from Roche Australia (donated antibodies for further research in this field) outside the submitted work. I.M. Poynten reports other from Seqirus (travel funding) outside the submitted work. M. Molano reports grants from Cancer Council Victoria (project: evaluating molecular biomarkers of anal cancer risk, application no. APP1130507) during the conduct of the study. D.A. Machalek reports nonfinancial support from MSD and Seqirus, grants from Seqirus, and other from Roche Diagnostics (manuscript license sponsorship) outside the submitted work. F. Jin reports grants from the National Health and Medical Research Council and Cancer Council New South Wales during the conduct of the study. S.M. Garland reports grants (to institution for researcher-initiated grant for HPV young women's study), personal fees (lecture fees; work performed in personal time), and other from Merck (global advisory board member for HPV) outside the submitted work. A.E. Grulich reports grants from the National Health and Medical Research Council during the conduct of the study. A.M. Cornall reports grants from Cancer Council Victoria during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.